News|Articles|September 19, 2023

Climedo Upgrades Progression and Benchmarking Features

Updates provide comprehensive insights for tracking patient progression and analyzing clinical data, company says.

Climedo, an eCOA and electronic data captire (EDC) software company, has released a number of enhancements to its progression and benchmark features for clinical studies. According to the company, these updates mark a significant milestone in empowering healthcare professionals (HCPs) and researchers with more comprehensive insights for tracking patient progression and analyzing clinical data.

The upgraded progression and benchmarking features include progression comparison, benchmarking refinement, robust data filtering, rich text functionality, and a dashboard selection overhaul.

Reference: Climedo Releases Improved Features to Revolutionize Clinical Data Insights and Progress Tracking. Climedo. September 19, 2023. Accessed September 19, 2023. https://climedo.de/en/press/climedo-releases-improved-features-to-revolutionize-clinical-data-insights-and-progress-tracking/

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

October 15th, 2026

The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution

In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.

October 15th, 2026

ACT Brief: EHR-to-EDC Connectivity, FDA’s Rare Disease Framework, and Barriers to Oncology RWE

In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.

October 14th, 2026

FDA Launches Rare Disease Framework Initiative to Reimagine Drug Development for Small Patient Populations

A new white paper and public engagement process outline the FDA’s commitment to building fit-for-purpose evidentiary standards, stronger patient voice integration, and greater regulatory predictability across rare disease drug development and review.

© putilov_denis - © putilov_denis - stock.adobe.com

October 14th, 2026

Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection

Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.

October 14th, 2026

ACT Brief: Design Drivers of Trial Representation, eSource-to-EDC Data Automation, and Roche's ALK7 Obesity License

In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.

October 13th, 2026

IgniteData and RealTime Partner to Streamline Clinical Data Transfer From eSource to Sponsor Systems

The partnership gives RealTime's network of more than 3,000 research sites access to the Archer platform for direct, automated data transfer from eSource to any sponsor electronic data capture system or data destination.

October 13th, 2026

The Biggest Remaining Barriers to High-Quality RWE Across Oncology Data Platforms

In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, identify three persistent obstacles to consistent real-world evidence generation in oncology—inconsistent data capture, structural data limitations that modeling alone can't fix, and the need for earned generalizability through deliberate multi-site validation.

A case study of how an emerging biotech moved from targeted monitoring to full clinical operations and site management across multiple studies. Credit: Stock.Adobe.com/PHOTO4U

October 12th, 2026

Flexible Clinical Operations and Site Management Across a Diversified Biotech Portfolio: An Application of Quality by Design and Risk-Based Oversight

How a phased CRO partnership built on ICH E6(R2) and E6(R3) principles supported a multi-indication biotech portfolio.

Climedo Upgrades Progression and Benchmarking Features

Related to this article

Trending on Applied Clinical Trials Online

FDA Launches Rare Disease Framework Initiative to Reimagine Drug Development for Small Patient Populations

Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection

ACT Brief: Design Drivers of Trial Representation, eSource-to-EDC Data Automation, and Roche's ALK7 Obesity License

The Biggest Remaining Barriers to High-Quality RWE Across Oncology Data Platforms

IgniteData and RealTime Partner to Streamline Clinical Data Transfer From eSource to Sponsor Systems